Rituximab-Based Regimens for Treatment of Primary Gastric Diffuse Large B-Cell Lymphoma.
10.19746/j.cnki.issn.1009-2137.2022.03.016
- Author:
Shuang QU
1
;
Li-Sheng LIAO
1
;
Zhi-Hai ZHENG
1
;
Ying XIE
1
;
Wei-Min CHEN
1
;
Bi-Yun CHEN
2
Author Information
1. Department of Hematology, Fujian Provincial Hospital， Fujian Medical University, Fuzhou 350001, Fujian Province, China.
2. Department of Hematology, Fujian Provincial Hospital， Fujian Medical University, Fuzhou 350001, Fujian Province, China,E-mail: slyyxyk301@163.com.
- Publication Type:Journal Article
- Keywords:
chemotherapy;
diffuse large B-cell lymphoma;
prognosis;
stomach
- MeSH:
Adult;
Aged;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Cyclophosphamide/therapeutic use*;
Disease-Free Survival;
Doxorubicin/therapeutic use*;
Female;
Humans;
L-Lactate Dehydrogenase;
Lymphoma, Large B-Cell, Diffuse/pathology*;
Male;
Middle Aged;
Prednisone/therapeutic use*;
Prognosis;
Retrospective Studies;
Rituximab/therapeutic use*;
Vincristine/therapeutic use*
- From:
Journal of Experimental Hematology
2022;30(3):760-764
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze clinical response of the Rituximab-based chemotherapy and prognostic features in patients with primary gastric diffuse large B-cell lymphoma (PGDLBCL).
METHODS:From June 2008 to December 2020, the data of 53 PGDLBCL patients were analyzed retrospectively.
RESULTS:The median age was 46(25-77) years old in 53 patients including 35 males and 18 females. Stomachache is the most common symptom. The diagnosis were confirmed in 47 patients by endoscopic biopsy and 6 patients by surgery. Twenty-six patients had Ⅰ/Ⅱ1 stage (Lugano staging system) disease and 27 cases had II2/IV stage disease. All patients were treated with chemotherapy, including RCHOP (25/53) and R-DA-EPOCH (28/53). Complete remission rate was 79.2%（42/53）. The 3-year and 5-year overall survival (OS) rates were 77.4% and 69.8%. Univariate analysis showed that lactate dehydrogenase(LDH), Lugano stage and lesion size affected OS. Multivariate Cox regression analysis revealed that IPI score and Lugano stage were independent prognosis risk factors affecting OS. The patients in the R-DA-EPOCH group presented better survival outcomes than those in the RCHOP group with late stage (P5-year OS=0.035).
CONCLUSION:Rituximab in combination with chemotherapy is the backbone of therapy for PGDLBCL. IPI score and Lugano stage are independent prognosis risk factors affecting OS of PGDLBCL. R-DA-EPOCH can be superior to R-CHOP as a first-line regimen in PGDLBCL patients with late stage.
